Login / Signup

Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response.

Mark A SamaanSiddharth BirdiMaria Sierra MoralesSailish HonapAravind Gokul TamilarasanGeorgina CunninghamIoannis KoumoutsosShuvra RayJoel MawdsleySimon H C AndersonJeremy SandersonPeter M Irving
Published in: Frontline gastroenterology (2019)
Our findings demonstrate VDZ dose intensification to be effective at achieving clinical response in half of patients. Low baseline CRP and response at week 12 are potential predictors of week 24 response.
Keyphrases
  • end stage renal disease
  • randomized controlled trial
  • ejection fraction
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes
  • human health